Saltar al contenido
Merck

A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers.

Nature communications (2022-04-24)
Pranavi Koppula, Guang Lei, Yilei Zhang, Yuelong Yan, Chao Mao, Lavanya Kondiparthi, Jiejun Shi, Xiaoguang Liu, Amber Horbath, Molina Das, Wei Li, Masha V Poyurovsky, Kellen Olszewski, Boyi Gan
RESUMEN

Targeting ferroptosis, a unique cell death modality triggered by unrestricted lipid peroxidation, in cancer therapy is hindered by our incomplete understanding of ferroptosis mechanisms under specific cancer genetic contexts. KEAP1 (kelch-like ECH associated protein 1) is frequently mutated or inactivated in lung cancers, and KEAP1 mutant lung cancers are refractory to most therapies, including radiotherapy. In this study, we identify ferroptosis suppressor protein 1 (FSP1, also known as AIFM2) as a transcriptional target of nuclear factor erythroid 2-related factor 2 (NRF2) and reveal that the ubiquinone (CoQ)-FSP1 axis mediates ferroptosis- and radiation- resistance in KEAP1 deficient lung cancer cells. We further show that pharmacological inhibition of the CoQ-FSP1 axis sensitizes KEAP1 deficient lung cancer cells or patient-derived xenograft tumors to radiation through inducing ferroptosis. Together, our study identifies CoQ-FSP1 as a key downstream effector of KEAP1-NRF2 pathway and as a potential therapeutic target for treating KEAP1 mutant lung cancers.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anticuerpo anti-fosfo-histona H2A.X (Ser139), clon JBW301, clone JBW301, Upstate®, from mouse
Sigma-Aldrich
Ferrostatin-1, ≥95% (HPLC)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from baker′s yeast (S. cerevisiae), Type IX, lyophilized powder, 200-400 units/mg protein (modified Warburg-Christian)
Sigma-Aldrich
Monoclonal Anti-Vinculin antibody produced in mouse, clone VIN-11-5, ascites fluid